期刊文献+

严重自身免疫性疾病患者的外周血CD34^+细胞动员 被引量:3

Mobilization of peripheral blood CD34^+ cell in the patients with severe autoimmune disease
下载PDF
导出
摘要 目的探讨严重自身免疫性疾病患者外周血CD34+细胞动员的规律和安全性。方法以CTX+rhG-CSF方案对严重自身免疫性疾病患者进行外周血CD34+细胞动员。结果动员后可获得单个核细胞(MNC)4.52(1.15~14.05)×108/kg,其中CD34+细胞为5.18(1.30~26.35)×106/kg。19例次患者注射CTX后ANC<0.5×109L-1,获得MNC 4.33(1.15~9.5)×108/kg、CD34+细胞5.16(1.30~26.35)×106/kg;23例次患者注射CTX后ANC≥0.5×109L-1,获得MNC 4.45(1.21~14.05)×108/kg、CD34+细胞5.41(1.0~24.10)×106/Kg。2组间无差异。动员过程中原发病无明显恶化,所有患者原发病均得到不同程度的缓解。其中SLE患者SLE-DAI评分由17(12~24)分降至3(0~4)分(P<0.01),RA患者均达到ACR20标准。1例患者出现急性肾功能衰竭,1例患者死于TTP,3例患者动员失败。结论以CTX+rhG-CSF方案可有效地动员出足够的CD34+细胞,并能缓解原发病。动员过程中不良反应可耐受,但仍发生严重并发症甚至死亡。在少数动员失败的患者中,原因尚需进一步探讨。 Objective To evaluate the feasibility and safety of peripheral CD34^+ cell mobilization in the patients with severe autoimmune disease. Methods The patients were mobilized by the regimen of cyclophosphamide + rhG-CSF. Results After mobilization, the MNC and CD34^+ cells were gained by a median of 4.52( 1.15 - 14.05 )× 10^8/kg and 5.18(1.30 - 26.35) ×10^6/kg respectively. There were 19 case times among which the patients' ANC 〈 (0.5× 10^9/L, and 23 times of patients' ANC≥0.5 ×10^9/L. Comparing these two groups of patients, the MNC yields were a mean of 4.33 ( 1.15- 9.5 )×10^8/kg and 4.45 ( 1.21 - 14.05 )× 10^8/kg respectively ; and the CD34^+ cells yields were a median of 5.16( 1.30 - 26.35)× 10^6/kg and 5.41 ( 1.0 - 24.10)× 10^6/kg respectively. The underlying diseases were not exacerbated but ameliorated more or less by mobilization. In SLE group, SLE-DAI score decreased from mean of 17( 12 - 24) points to 3(0 - 4) points (P 〈 0.01 ). For RA patients, an ACR20 response was achieved in all five patients. One pa- tient suffered acute renal failure, one died of thrombotic thrombocytopenic purpura (TTP). Failed mobilization occurred in three patients. Conclusion Sufficient CD34^+ cells could be mobilized by the low dose of cyclophosphamide and rhGCSF. It not only appropriated in effectiveness and safety but also ameliorate the disease.
出处 《基础医学与临床》 CSCD 北大核心 2006年第4期405-408,共4页 Basic and Clinical Medicine
关键词 自身免疫性疾病 造血干细胞动员 autoimmune disease heamatopoietie stem cell mobilization
  • 相关文献

参考文献7

  • 1Storb RF,Lucarelli G,McSweeney PA,et al.Hematopoietic cell transplantation for benign hematological disorders and solid tumors[M]//Hematology.Washington:Am Soc Hematol Educ Program,2003 (1):372-397. 被引量:1
  • 2Prevoo ML,Van't Hof MA,Kuper HH,et al.Modified disease activity scores that include twenty-eight-joint counts:Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis[J].Arthritis Rheum,1995,38:44-48. 被引量:1
  • 3周道斌,赵岩,王书杰,李太生,张洁萍,赵永强,段云,张奉春,唐福林,白连钧,崔巍,吴蓓,张福全,沈悌.自体纯化CD_(34)^+细胞移植治疗严重自身免疫性疾病的初步研究[J].中华血液学杂志,2003,24(9):460-463. 被引量:6
  • 4Korbling M.Mobilization regimen for harvesting autologous and allogeneic peripheral blood stem cells[M]//Kerry Atkinson,Richard Champlin,Jerome Ritz,et al.Clinical bone marrow and blood stem cell transplantation.3rd ed.Cambridge:Cambridge University Press,2004:383-415. 被引量:1
  • 5刘艳荣,陈珊珊,于弘.流式细胞术计数CD34阳性细胞的标准化与质量控制[J].中国实验血液学杂志,2000,8(4):302-306. 被引量:17
  • 6Burt RK,Fassas A,Snowden J,et al.Collection of hematopoietic stem cell from patients with autoimmune disease[J].Bone Marrow Transplant,2001,28:1-12. 被引量:1
  • 7Martino R,Sureda A,Brunet S,et al.Peripheral blood stem cell mobilization in refractory autoimmune Evans syndrome:a cautionary case report[J].Bone Marrow Transplant,1997,20:521. 被引量:1

二级参考文献31

  • 1Bingham SJ, Snowden JA, Emery P. Autologous blood stem cell transplantation as therapy for autoimmune diseases. Ann Med, 2000, 32:615-621. 被引量:1
  • 2Jantunen E, Myilykangas-Iawsujarvi R. Stem cell transplantation for treatment of severe autoimmune disease: current status and future perspectives. Bone Marrow Transplant, 2000, 25: 351-356. 被引量:1
  • 3Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35: 630-640. 被引量:1
  • 4Prevoo ML, Van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.Arthritis Rheum, 1995,38:44-48. 被引量:1
  • 5Richard AN. Prospect of stem cell transplantation in antoimmtme disease.J Clin Immunol, 2000, 20:38-45. 被引量:1
  • 6Euler HH, Marmont AM, Bacigalupo A, et al. Early recurrence or persistence of autoinrntme diseases after unmanipulated autologous stem cell transplantation. Blood, 1996, 88: 3621-3625. 被引量:1
  • 7Cooley HM, Snowden JA, Grigg AP, et al. Outcome of rheumatoid arthritis and psoriasis following autologous stem cell transplantation for hematologic malignancy. Arthritis Rheum, 1997, 40: 1712-1715. 被引量:1
  • 8McSweeney PA, Furst DE, Storek J, et al. High-dose immunosuppressive therapy(HDIT) using total body irradiation (TBI), cyclophosphamide(Cy) and ATG with autologous CD34-selected peripheral blood stem cell(PBSC) rescue and treatment for severe systemic sclerosis (SSc). Blood,1998, 92 Suppl 1: 295a. 被引量:1
  • 9Tyndall A, Fassas A, Passweg J, et al. Autologous haematopoietie stem cell transplants for antoimmtme disease-feasibility and transplant-related mortality. Bone Marrow Transplant, 1999, 24: 729-734. 被引量:1
  • 10Leona AH, Boeckh M, Heather H, et al. Increased incidence of cytomegalovirus disease after autologous CD34-selected peripheral blood stem cell transplantation. Blood, 1999, 94: 4029-4035. 被引量:1

共引文献21

同被引文献24

  • 1赵岩,周道斌,冷晓梅,王书杰,李太生,段云,沈悌,赵永强,张洁萍,白连钧,崔巍,张福全,曾小峰,张奉春,董怡,唐福林.自体外周血干细胞移植治疗系统性自身免疫病[J].中华医学杂志,2004,84(24):2077-2081. 被引量:17
  • 2Lim SH, Kell J, Bashi W, et al. Peripheral blood stem-cell transplantation for refractory autoimmune thrombocytopenic purpura[J]. Lancet,1997, 340:475. 被引量:1
  • 3Marmont AM, van Lint MT, Occhini D, et al. Failure of autologous stem cell transplantation in refractory thrombocytopenic purpura [J]. Bone Marrow Transplant, 1998,22 (8) :827 - 828. 被引量:1
  • 4Musso M, Porretto F, Crescimanno A, et al. Intense immunosuppressive therapy followed by autologous peripheral blood selected progenitor cell reinfusion for severe autoimmune disease[J]. Am J nematol, 2001, 66(2) :75 -59. 被引量:1
  • 5Zavdan MA, Turner C, Miller AM. Resolution of chronic idiopathic thrombocytopenia purpura following syngeneic peripheral blood progenitor transplant [J]. Bone Marrow Transplant, 2002, 29 ( 1 ) :87 - 89. 被引量:1
  • 6Passweg JR. Haematopoietic stem cell transplantation for immune thrombopenia and other refractory autoimmune cytopenias[J]. Best Pract Res Clin Haematol, 2004,17(2): 305 - 315. 被引量:1
  • 7Richard D, Patrick F, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte depleted peripheral blood stem cell support for treatment of refractory chronic autoimmune thrombocytopenia [J]. Blood, 2003, 101:71 -77. 被引量:1
  • 8Tsukamoto H,Nagafuji K, Horiuchi T, et al. A phase Ⅰ-Ⅱ trial of autologous peripheral blood stem-cell transplantation in the treatment of refractory autoimmune disease[J]. Ann Rheum Dis ,2006,65:508 - 514. 被引量:1
  • 9Megan S, Boris N, Treatment of severe autoimmune disease by stem-cell transplantation [J]. NATUER, 2005, 435 (2) :620 - 627. 被引量:1
  • 10Stevens W, Koene H, Zwaginga J, et al. Chronic idiopathic thrombocytopenic purpura: present strategy, guidelines and new insights[J]. Neth J Med, 2006,64(10) :356 - 363. 被引量:1

引证文献3

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部